Bristol-Myers Q3 rev $10.97B; GAAP EPS $0.93, non-GAAP $2.00; Mirati acquisition

BRISTOL MYERS SQUIBB CO

2023-Q3 EPS reported $2.99 revenue$33,529,000,000

Q3 revenues $10,966M, down 2% YoY (3% ex-FX); GAAP EPS $0.93 (+24%), non-GAAP EPS $2.00 (+1%).
In-line and new product portfolio revenue grew 8% YoY (7% ex-FX).
Acquired IPRD and licensing charges reduced GAAP and non-GAAP EPS by $0.03 per share.
Planned acquisition of Mirati Therapeutics to strengthen oncology pipeline; terms not disclosed.
Adjusted 2023 GAAP EPS guidance downward; raised midpoint of non-GAAP EPS guidance range.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BRISTOL MYERS SQUIBB CO reported the third quarter of 2023 results: revenue $10,966, EPS 0.93.

Period: the third quarter of 2023
Revenue: $10,966
EPS: 0.93
Result: reported results

Exact text from the filing

business development opportunities that benefit patients." 1 Third Quarter $ amounts in millions, except per share amounts 2023 2022 Change Change Excl. F/X** Total Revenues $10,966 $11,218 (2) % (3) % Earnings per share - GAAP* 0.93 0.75 24 % N/A Earnings per share - Non-GAAP* 2.00 1.99 1 % N/A * GAAP and Non-GAAP earnings per share include the net impact of

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

BRISTOL MYERS SQUIBB CO filing history →

Source: SEC EDGAR

accession 0000014272-23-000179

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.